Tempest Therapeutics/$TPST
1D1W1MYTD1Y5YMAX
Capital at risk
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
- Ticker
- $TPST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4
- Headquarters
- Brisbane, United States
- Website
- www.tempesttx.com
TPST Metrics
BasicAdvanced
$19M
-
-$4.56
-1.68
-
Price and volume
Market cap
$19M
Beta
-1.68
52-week high
$12.23
52-week low
$0.74
Average daily volume
4.5M
Financial strength
Current ratio
0.381
Quick ratio
0.175
Long term debt to equity
-5.755
Total debt to equity
-6.936
Profitability
EBITDA (TTM)
-21.411
Management effectiveness
Return on assets (TTM)
-79.37%
Return on equity (TTM)
-931.14%
Valuation
Price to book
-17.74
Price to tangible book (TTM)
-17.74
Price to free cash flow (TTM)
-0.519
Free cash flow yield (TTM)
-192.85%
Free cash flow per share (TTM)
-2.333
Growth
Earnings per share change (TTM)
-67.28%
3-year earnings per share growth (CAGR)
-47.39%
Upcoming events
No upcoming events
TPST News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.